<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96793">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844687</url>
  </required_header>
  <id_info>
    <org_study_id>Study Number CBD-001</org_study_id>
    <nct_id>NCT01844687</nct_id>
  </id_info>
  <brief_title>Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana</brief_title>
  <official_title>Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steve Sparenborg</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400,
      800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and
      cardiovascular effects. This experiment is expected to reveal CBD's intrinsic effects when
      combined with placebo marijuana, as well as its ability to modulate the behavioral effects
      of active marijuana.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance Battery</measure>
    <time_frame>10 minutes</time_frame>
    <description>Cognitive tasks such as the Digit-Symbol Substitution Task, Continuous Performance Task and Digit Span Backwards</description>
  </primary_outcome>
  <other_outcome>
    <measure>Marijuana Rating Form</measure>
    <time_frame>2 minutes</time_frame>
    <description>Participants rate the strength, liking, desire to take again, good drug effect and bad drug effect of smoked marijuana.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cannabidiol Capsule Rating Form</measure>
    <time_frame>2 minutes</time_frame>
    <description>Participants rate the capsule strength, capsule liking, desire to take again, good drug effect and bad drug effect.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mood Scale</measure>
    <time_frame>2 minutes</time_frame>
    <description>Visual analog scale used to assess subjective drug effects including physical symptoms and mood.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Smoking, Marijuana</condition>
  <arm_group>
    <arm_group_label>Active or inactive MJ with 0, 200, 400, or 800 mg CBD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each subject in the study will be tested on eight days, each day receiving a different combination of active/inactive marijuana cigarette plus 0, 200, 400 or 800 mg of cannabidiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cannabidiol</intervention_name>
    <arm_group_label>Active or inactive MJ with 0, 200, 400, or 800 mg CBD</arm_group_label>
    <other_name>cannabidiol is abbreviated CBD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between the ages of 18 and 50.

          -  Current marijuana use: Minimum of four times per week, 0.5 joints per occasion during
             the preceding 4 weeks.

          -  Able to perform study procedures

          -  Women practicing an effective form of birth control

        Exclusion Criteria:

          -  Female subjects who are currently pregnant or breastfeeding.

          -  Current, repeated illicit drug use other than marijuana

          -  Presence of significant medical illness

          -  History of heart disease

          -  Request for drug treatment

          -  Current parole or probation

          -  Recent history of significant violent behavior

          -  Major psychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert J Malcolm, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Walsh, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Wolf</last_name>
      <phone>859-257-1612</phone>
    </contact>
    <investigator>
      <last_name>Sharon Walsh, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bennett Wechsler, B.S.</last_name>
      <phone>212-543-5175</phone>
      <email>wechsle@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Margaret Haney, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Drug and Alcohol Programs, Room 459 North, 67 President St.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Huebner, BS RN MPH</last_name>
      <phone>843-792-1901</phone>
      <email>huebnerk@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Irk, B.S.</last_name>
      <phone>843-792-1231.</phone>
      <email>irkki@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Malcolm, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Drug Abuse (NIDA)</investigator_affiliation>
    <investigator_full_name>Steve Sparenborg</investigator_full_name>
    <investigator_title>Pharmacotherapy Clinical Trials Team Leader</investigator_title>
  </responsible_party>
  <keyword>reinforcement, good drug effect, high, mood, cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
